Verastem Oncology has dosed the first patient in TARGET-D 202, a global Phase 2 trial evaluating its investigational oral drug VS-7375 in previously treated, advanced non-small cell lung cancer carrying a KRAS G12D mutation. The registration-directed study will administer VS-7375 at 900 mg once daily and includes a separate cohort for patients with asymptomatic, untreated brain metastases.
The July 22, 2026 announcement moves VS-7375 beyond dose exploration and into a disease-specific study intended to define whether its early clinical activity can become a credible regulatory package. That is strategically important because approximately 5% of non-small cell lung cancers carry KRAS G12D, yet no treatment specifically targeting this mutation has been approved by the United States Food and Drug Administration.
First-patient dosing is an operational milestone rather than evidence of efficacy. TARGET-D 202 must now establish a reproducible response rate, demonstrate that responses last, confirm that the 900 mg dose remains tolerable with longer exposure and show whether VS-7375 has activity in patients whose disease has already progressed after platinum chemotherapy and immune checkpoint inhibition.
The trial therefore represents both an expansion opportunity and a considerable test for Verastem Oncology. The company is advancing an inhibitor with a differentiated dual-state mechanism into a competitive field where rival KRAS G12D programmes already possess clinical data, expedited regulatory designations and increasingly ambitious late-stage development plans.
Why does first-patient dosing matter when TARGET-D 202 still has to prove registrational value?
TARGET-D 202 is an open-label Phase 2 study involving patients with unresectable locally advanced or metastatic KRAS G12D-mutated non-small cell lung cancer whose disease progressed after platinum-based chemotherapy and an anti-PD-1 or anti-PD-L1 therapy. The trial registry lists estimated enrolment of 105 participants, estimated primary completion in June 2027 and study completion in December 2028.
The term registration-directed indicates that Verastem Oncology has designed the programme with a potential regulatory strategy in mind. It does not mean the trial is guaranteed to support an application, qualify for accelerated approval or eliminate the need for a randomized confirmatory study.
For a single-arm oncology trial to become regulatory evidence, the magnitude and durability of tumour responses must be interpretable against available treatment options. Patient selection, prior therapies, independent radiological review, response confirmation, follow-up duration and safety exposure will all determine whether the eventual dataset is persuasive.
The clinical bar may also move while TARGET-D 202 is enrolling. Other targeted agents could report stronger data, treatment sequencing could change and new therapies may become available for previously treated non-small cell lung cancer. Verastem must therefore produce evidence that is competitive with the standard of care at the time of any regulatory submission, not merely the standard that existed when the protocol was written.
What does the 900 mg dose reveal about Verastem’s development strategy for VS-7375?
VS-7375 is designed to inhibit both the active, GTP-bound “ON” state and inactive, GDP-bound “OFF” state of KRAS G12D. Verastem Oncology argues that this dual-state binding could provide more sustained pathway inhibition than compounds designed primarily around a single KRAS conformation.
That mechanism is scientifically interesting, but a mechanistic distinction is not automatically a clinical advantage. The programme will ultimately be judged through tumour responses, durability, progression control, tolerability, dose intensity and performance in clinically difficult patient populations.
Verastem selected 900 mg once daily as the recommended Phase 2 dose after pharmacokinetic analyses from TARGET-D 101 indicated that the dose achieved the company’s targeted plasma exposure and separated from the exposure observed at 600 mg. The company has also reported evidence of dose-dependent activity across parts of its broader solid-tumour programme.
The move into TARGET-D 202 effectively converts those pharmacokinetic and early activity observations into a testable therapeutic proposition. Verastem must show that the higher exposure at 900 mg produces sufficient additional anti-tumour activity without creating toxicity that compromises treatment continuity.
That balance is particularly important for oral targeted therapies. A dose may achieve strong laboratory exposure while proving difficult to maintain because of gastrointestinal adverse events, fatigue, laboratory abnormalities or cumulative tolerability problems. Dose reductions and interruptions can weaken effective drug exposure even when the nominal starting dose appears pharmacologically attractive.
How mature is the NSCLC evidence supporting this registration-directed Phase 2 programme?
The supporting non-small cell lung cancer evidence remains preliminary. In June 2026, Verastem Oncology reported early activity at the 600 mg monotherapy dose in TARGET-D 101, but said that only one of more than 20 patients in the cohort had at least six months of follow-up at the data cutoff.
The company highlighted one 77-year-old woman whose tumour reduction deepened from an unconfirmed partial response at week six to a confirmed 49% reduction at week 12. That individual case supports biological activity, but it does not establish a cohort-level response rate, median duration of response or progression-free survival.
Verastem has not yet disclosed a mature aggregate efficacy dataset for the non-small cell lung cancer population treated at 900 mg. The Phase 2 programme is therefore advancing on a combination of pharmacokinetic exposure, activity observed across multiple tumour types, early lung cancer responses and the broader biological rationale for targeting KRAS G12D.
The preliminary safety dataset is larger. As of June 12, 2026, the company had evaluated VS-7375 monotherapy in 57 patients at 600 mg and 25 patients at 900 mg. Treatment-related adverse events were mainly nausea, vomiting and diarrhoea, with the company reporting that these events generally diminished after the first treatment cycle.
One Grade 3 nausea event was reported at 900 mg and resolved following optimization of antiemetic treatment. Verastem also reported no clinically meaningful cytopenias or liver-function abnormalities at the two dose levels. These findings remain company-reported, however, and longer treatment exposure is necessary to determine whether the initial tolerability pattern persists.
The central evidence gap is therefore not whether VS-7375 can produce tumour shrinkage. Early observations suggest that it can. The unanswered questions concern how often responses occur, how durable they are, whether activity extends across clinically important subgroups and whether patients can remain on the 900 mg dose long enough to receive sustained benefit.
Why could the untreated brain metastases cohort become a meaningful differentiator?
TARGET-D 202 includes a cohort of patients with asymptomatic, untreated brain metastases, an inclusion that could increase the clinical relevance of the study if VS-7375 demonstrates intracranial activity.
Brain metastases are common during the course of advanced non-small cell lung cancer and can substantially complicate treatment. Patients with active or untreated central nervous system disease have also frequently been excluded from early oncology trials, leaving clinicians with limited evidence when targeted therapies enter routine practice.
Verastem Oncology said the cohort was supported by activity observed in preclinical intracranial tumour models. Preclinical findings cannot establish human central nervous system efficacy, but they provide a rationale for directly evaluating a patient group that is difficult to treat and commercially relevant.
The quality of this cohort’s eventual results will depend on more than whether extracranial tumours shrink. Investigators will need to evaluate intracranial response, duration of central nervous system control, development of new brain lesions, use of radiation and corticosteroids, neurological progression and overall safety.
Demonstrated intracranial activity could distinguish VS-7375 from programmes that generate strong systemic responses but have uncertain brain penetration. Conversely, weak or inconsistent central nervous system activity would limit the value of the cohort even if the broader study produces an acceptable systemic response rate.
How does VS-7375 enter a KRAS G12D field where competition is already moving quickly?
Verastem Oncology is not entering an empty market. Revolution Medicines is developing zoldonrasib, an oral RAS(ON) G12D-selective inhibitor that has already generated Phase 1 data in previously treated KRAS G12D non-small cell lung cancer.
At the 2026 American Association for Cancer Research annual meeting, Revolution Medicines presented safety data from 40 patients treated at the recommended Phase 2 dose and efficacy analyses from 27 patients meeting defined prior-treatment and follow-up criteria. Zoldonrasib also received Breakthrough Therapy designation in January 2026 for previously treated KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer.
Those developments mean VS-7375 will be assessed against another mutation-selective programme with a more mature lung cancer dataset. Cross-trial numerical comparisons would remain unreliable because patient selection, follow-up, prior treatment, response assessment and dose exposure may differ.
The competitive question is broader than which drug reports the highest early response percentage. The successful programme will need to combine meaningful and durable efficacy with a manageable safety profile, convenient administration, reliable manufacturing, regulatory clarity and a development strategy that supports combinations and earlier treatment settings.
Verastem’s dual ON/OFF mechanism may offer differentiation, while zoldonrasib’s RAS(ON) approach has already produced a larger disease-specific evidence base. The field may eventually support more than one drug, particularly if the agents develop different profiles across lung, pancreatic and colorectal cancers. However, the first programmes to deliver convincing pivotal evidence could gain advantages in physician familiarity, trial recruitment, regulatory interaction and combination development.
What will regulators need beyond tumour shrinkage to evaluate VS-7375’s benefit-risk profile?
VS-7375 received Fast Track designation in June 2026 for adults with KRAS G12D-mutated unresectable locally advanced or metastatic non-small cell lung cancer previously treated with platinum chemotherapy and an anti-PD-1 or anti-PD-L1 antibody. Fast Track can provide more frequent regulatory communication and potential eligibility for rolling review, but it is not an approval or confirmation of efficacy.
In single-arm oncology programmes, objective response rate and duration of response have frequently supported accelerated approval when the clinical context and unmet need justify that approach. The Food and Drug Administration has nevertheless stated that randomized controlled studies generally provide a more robust assessment and are preferred where feasible.
For TARGET-D 202, regulators are likely to examine whether responses are independently confirmed, whether they persist for a clinically meaningful period and whether the study population accurately represents the proposed indication. Safety interpretation will require sufficient patient numbers and follow-up to identify uncommon or cumulative adverse events.
Dose justification will also be important. The 900 mg selection must be supported by pharmacokinetics, exposure-response analyses and evidence that a lower dose would not deliver a similar benefit with improved tolerability. Modern oncology development increasingly requires sponsors to demonstrate that the chosen dose is optimized rather than merely the highest dose considered manageable.
Verastem has indicated that it plans to discuss Phase 3 designs with the Food and Drug Administration before the end of 2026 and aims to begin pivotal first-line studies during the first half of 2027. Those meetings will reveal whether regulators view the Phase 2 programme primarily as a potential accelerated-approval dataset, a bridge into randomized development or both.
Can Verastem finance three Phase 2 trials while preparing for pivotal development?
Verastem Oncology ended March 2026 with $181.7 million in cash, cash equivalents and investments and expected its resources to fund operations into the first half of 2027. The company also generated $18.7 million in first-quarter net product revenue from AVMAPKI FAKZYNJA CO-PACK, its approved treatment for low-grade serous ovarian cancer.
Commercial revenue gives Verastem a funding source that many clinical-stage biotechnology companies lack, but its development commitments are expanding rapidly. The company is advancing separate Phase 2 studies in pancreatic cancer, lung cancer and colorectal cancer while continuing TARGET-D 101 and planning multiple Phase 3 programmes.
Operating activities used approximately $52.1 million of cash during the first quarter. That rate may change as product sales grow, but broader clinical enrolment, drug manufacturing, regulatory preparation and pivotal study initiation are likely to keep research and development spending elevated.
The timing creates a financing question. Verastem’s stated runway reaches approximately the period when it expects to begin the proposed Phase 3 trials. Unless commercial revenue grows sufficiently or development spending is phased differently, the company could require additional capital, a partnership or another strategic funding source before the VS-7375 programme reaches decisive late-stage readouts.
What does Verastem’s stock performance indicate about investor expectations for VS-7375?
Verastem shares closed at $5.86 on July 22, down approximately 2.3% during the session. Because the first-patient announcement was issued at 4:01 p.m. Eastern Time, after regular market trading ended, the closing movement should not be interpreted as a reaction to TARGET-D 202.
The stock was approximately 2.3% higher than its July 15 close and about 37.9% above its June 22 level. It nevertheless remained almost 48% below the upper end of its recent 52-week range of $3.43 to $11.25.
That performance suggests improved sentiment around Verastem’s broader commercial and pipeline progress, while also showing that investors have not assigned certainty to the VS-7375 opportunity. The stock remains exposed to clinical data maturity, product-launch execution, future financing requirements and competitive results from other KRAS-directed programmes.
TARGET-D 202 is best viewed as a long-term pipeline catalyst rather than an immediate value-creating event. First-patient dosing confirms that the study is operational, but valuation will be influenced far more heavily by enrolment progress, mature TARGET-D 101 data and the first disease-specific efficacy results from the Phase 2 trial.
Which milestones will determine whether TARGET-D 202 becomes more than a pipeline expansion?
Verastem expects to provide another TARGET-D 101 update during the second half of 2026. That disclosure should be the first opportunity to determine whether the early non-small cell lung cancer activity is becoming a consistent cohort-level signal.
Investors and clinical observers will focus on the number of evaluable patients, confirmed objective response rate, depth of response, duration of response, progression-free survival, dose reductions and treatment discontinuations. The relationship between outcomes at 600 mg and 900 mg will also influence confidence in the Phase 2 dose.
Completion of enrolment across TARGET-D 201, TARGET-D 202 and TARGET-D 203 by the end of 2026 would demonstrate execution, but speed cannot replace data quality. Verastem must enrol appropriate patients, maintain protocol consistency across global sites and generate follow-up long enough to distinguish temporary tumour shrinkage from durable clinical activity.
The proposed Food and Drug Administration meeting on Phase 3 designs will be another important signal. Clear agreement on patient populations, comparators, endpoints and sequencing could reduce strategic uncertainty ahead of pivotal development.
TARGET-D 202 gives Verastem Oncology a credible route to test VS-7375 in a molecularly defined lung cancer population with no approved KRAS G12D-specific therapy. The programme’s real value will emerge only when the 900 mg dose shows reproducible responses, durable benefit, acceptable long-term tolerability and, potentially, meaningful activity against untreated brain metastases. First-patient dosing has started that test. It has not yet answered it.
